Emanuelli Research and Development Center LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$837,317	434
2024	Research	$553,778	86
2023	Research	$1,706,085	113
2022	Research	$1,019,052	36
2021	Research	$1,149,140	13
2020	Research	$2,108,079	13
2019	Research	$921,964	34

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $4,763,401 33 payments
Genentech, Inc. $1,775,420 152 payments
Regeneron Pharmaceuticals, Inc. $1,626,166 460 payments
F. Hoffmann-La Roche AG $71,551 76 payments
AbbVie, Inc. $58,878 8 payments

Studies the money was for Research payments · program years 2019–2025

A 96-Week, Two-Arm, Randomized, Single-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 MG Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy $1,077,704 7 payments
Faricimab for Under Represented Patients With Dme $1,035,645 107 payments
A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic MacUlar Edema $1,006,146 3 payments
A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $886,978 376 payments
A Multicenter Randomized Double Masked Phase 3A Study to Assess Safety and Efficacy of Brolucizumab 6 MG Q4 Weeks Compared to Aflibercept 2 MG Q4 Weeks in Patients With Neovascular Age Related MacUlar Degeneration Namd With Persistent Retinal Fluid $671,053 4 payments
A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $657,496 2 payments
A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due to MacUlar Edema (Me) Secondary to Central Retinal Vein Occlusion (Crvo) $614,683 3 payments
A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy $577,208 30 payments
A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics $439,225 14 payments
A Randomized, Active-Controlled, Subject and Investigator-Masked, Multiple Dose Proof-Of-Concept Study of Intravitreal Lka651 in Patients With Diabetic MacUlar Edema $391,909 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.